India Launches Nationwide HPV Vaccination Drive to Combat Cervical Cancer

India has embarked on a monumental nationwide Human Papillomavirus (HPV) vaccination campaign, a critical public health initiative aimed at eradicating cervical cancer, which remains the second most common cancer and a leading cause of cancer-related deaths among women in the country. Launched on February 28, 2026, the program targets approximately 1.2 crore (12 million) girls aged 14 years, providing the Gardasil-4 vaccine free of cost through government health facilities across all states and union territories. This ambitious endeavor is a significant step towards realizing the vision of 'Swasthya Nari' (Healthy Woman) and aligns with the global call to eliminate cervical cancer by 2030. The campaign's nationwide rollout signifies a decisive move in India's public health journey, emphasizing prevention, protection, and equity in women's healthcare. The decision to administer a single dose of the Gardasil-4 vaccine is based on extensive global scientific evidence, including recommendations from the World Health Organization's (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization. This single-dose strategy is recognized for providing robust and durable protection, comparable to two-dose schedules, especially when administered to adolescent girls before potential exposure to the virus. The single-dose approach also enhances affordability and simplifies implementation, addressing logistical challenges and improving vaccine uptake. Cervical cancer poses a significant health burden in India, with an estimated 120,000 new cases and nearly 80,000 deaths annually. India accounts for a substantial proportion of the global cervical cancer burden, contributing to approximately one-fifth of new cases and nearly a quarter of deaths worldwide. Persistent infection with high-risk HPV types, particularly HPV types 16 and 18, is the primary cause of cervical cancer. The Gardasil-4 vaccine specifically protects against these cancer-causing strains, as well as HPV types 6 and 11, which are responsible for genital warts. By preventing HPV infections, the vaccination program aims to significantly reduce the incidence of cervical cancer and other HPV-related cancers, thereby averting millions of preventable deaths over the lifetime of vaccinated individuals. The nationwide campaign is a multi-faceted approach that includes screening, early diagnosis, and timely treatment, complementing the vaccination drive to combat cervical cancer comprehensively. The vaccination program is being managed through India's U-WIN digital platform, designed to capture end-to-end immunization records and monitor vaccine stocks, similar to the Co-WIN platform used during the COVID-19 pandemic. This digital infrastructure is crucial for ensuring efficient logistics, preventing supply shortages, and monitoring coverage across the country. While the national campaign uses Gardasil-4, an Indian-made quadrivalent HPV vaccine called Cervavac has also been developed and approved. However, Cervavac has not yet been included in the national immunization program due to ongoing research by the Indian Council of Medical Research (ICMR) to assess the long-term efficacy of its single-dose regimen. The decision to proceed with Gardasil initially was also influenced by Gavi, the Vaccine Alliance's support, which provided a limited supply of vaccines. The inclusion of Cervavac in the national program is anticipated once its single-dose effectiveness is fully validated and prequalification for single-dose use is obtained from the WHO. Despite the significant progress and the robust scientific backing for HPV vaccination, historical challenges such as vaccine hesitancy, misinformation, and accessibility have been noted. Earlier vaccination drives in states like Sikkim and Punjab, as well as a pilot project in Delhi, faced low uptake. To build public trust and ensure successful implementation, sustained political commitment and widespread awareness campaigns are essential. The voluntary nature of the vaccination, coupled with the mandatory requirement for parental consent, underscores the government's commitment to ethical implementation. The HPV vaccination program is a vital component of India's strategy to achieve the WHO's '90-70-90' targets for cervical cancer elimination, which aim for 90% of girls vaccinated by age 15, 70% of women screened by age 35 and 45, and 90% of women with precancer or cancer receiving adequate treatment. By prioritizing this preventive measure, India is poised to make a substantial impact on the global burden of cervical cancer and safeguard the health of future generations.

Frequently Asked Questions

Read Full Story on Quick Digest